Novartis, leader in the Population Health Management approach to expanding patient access to medicines, initiated a program in collaboration with NHS England to reduce low-density lipoprotein levels in patients with atherosclerotic cardiovascular disease, targeting up to 300,000 patients over three years. While the approach has seen success, challenges persist in its implementation, including technical, mindset, and regulatory barriers.